About this Journal Submit a Manuscript Table of Contents
Journal of Biomedicine and Biotechnology
Volume 2011 (2011), Article ID 947928, 4 pages
http://dx.doi.org/10.1155/2011/947928
Review Article

Anti-VEGF Therapy in Breast and Lung Mouse Models of Cancers

1Dipartimento di Patologia Generale, Seconda Università degli Studi di Napoli, Via L. De Crecchio, 7, 80138 Napoli, Italy
2Dipartimento di Biologia e Patologia Cellulare e Molecolare, Istituto di Endocrinologia ed Oncologia Sperimentale del CNR c/o, Facoltà di Medicina e Chirurgia di Napoli, Università degli Studi di Napoli “Federico II”, Via Pansini 5, 80131 Napoli, Italy

Received 20 September 2010; Accepted 1 October 2010

Academic Editor: Monica Fedele

Copyright © 2011 Di Domenico Marina et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Folkman, “Angiogenesis in cancer, vascular, rheumatoid and other disease,” Nature Medicine, vol. 1, no. 1, pp. 27–31, 1995. View at Scopus
  2. C. R. Pradeep, E. S. Sunila, and G. Kuttan, “Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies,” Integrative Cancer Therapies, vol. 4, no. 4, pp. 315–321, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. H. F. Dvorak, “Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy,” Journal of Clinical Oncology, vol. 20, no. 21, pp. 4368–4380, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. R. Roskoski Jr., “Vascular endothelial growth factor (VEGF) signaling in tumor progression,” Critical Reviews in Oncology/Hematology, vol. 62, no. 3, pp. 179–213, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. G. E. Konecny, Y. G. Meng, M. Untch et al., “Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients,” Clinical Cancer Research, vol. 10, no. 5, pp. 1706–1716, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. K. Miller, M. Wang, J. Gralow et al., “Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer,” The New England Journal of Medicine, vol. 357, no. 26, pp. 2666–2676, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. H. Hurwitz, L. Fehrenbacher, W. Novotny et al., “Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer,” The New England Journal of Medicine, vol. 350, no. 23, pp. 2335–2342, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. C. L. Roland, S. P. Dineen, K. D. Lynn et al., “Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts,” Molecular Cancer Therapeutics, vol. 8, no. 7, pp. 1761–1771, 2009. View at Publisher · View at Google Scholar · View at PubMed
  9. S. M. Wilhelm, L. Adnane, P. Newell, A. Villanueva, J. M. Llovet, and M. Lynch, “Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling,” Molecular Cancer Therapeutics, vol. 7, no. 10, pp. 3129–3140, 2008. View at Publisher · View at Google Scholar · View at PubMed
  10. M. E. Lacouture, S. Wu, C. Robert et al., “Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib,” Oncologist, vol. 13, no. 9, pp. 1001–1011, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. S. P. Dineen, K. D. Lynn, S. E. Holloway et al., “Vascular endothelial growth factor receptor 2 mediates macrophage infiltration into orthotopic pancreatic tumors in mice,” Cancer Research, vol. 68, no. 11, pp. 4340–4346, 2008. View at Publisher · View at Google Scholar · View at PubMed
  12. S. E. Holloway, A. W. Beck, L. Shivakumar, J. Shih, J. B. Fleming, and R. A. Brekken, “Selective blockade of vascular endothelial growth factor receptor 2 with an antibody against tumor-derived vascular endothelial growth factor controls the growth of human pancreatic adenocarcinoma xenografts,” Annals of Surgical Oncology, vol. 13, no. 8, pp. 1145–1155, 2006. View at Publisher · View at Google Scholar · View at PubMed
  13. G. Korpanty, J. G. Carbon, P. A. Grayburn, J. B. Fleming, and R. A. Brekken, “Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature,” Clinical Cancer Research, vol. 13, no. 1, pp. 323–330, 2007. View at Publisher · View at Google Scholar · View at PubMed
  14. B. Whitehurst, M. J. Flister, J. Bagaitkar et al., “Anti-VEGF-A therapy reduces lymphatic vessel density and expression of VEGFR-3 in an orthotopic breast tumor model,” International Journal of Cancer, vol. 121, no. 10, pp. 2181–2191, 2007. View at Publisher · View at Google Scholar · View at PubMed
  15. A. Mantovani, P. Allavena, A. Sica, and F. Balkwill, “Cancer-related inflammation,” Nature, vol. 454, no. 7203, pp. 436–444, 2008. View at Publisher · View at Google Scholar · View at PubMed
  16. S. P. Dineen, K. D. Lynn, S. E. Holloway et al., “Vascular endothelial growth factor receptor 2 mediates macrophage infiltration into orthotopic pancreatic tumors in mice,” Cancer Research, vol. 68, no. 11, pp. 4340–4346, 2008. View at Publisher · View at Google Scholar · View at PubMed
  17. W. Zhang, S. Ran, M. Sambade, X. Huang, and P. E. Thorpe, “A monoclonal antibody that blocks VEGF binding to VEGFR2 (KDR/Flk-1) inhibits vascular expression of Flk-1 and tumor growth in an orthotopic human breast cancer model,” Angiogenesis, vol. 5, no. 1-2, pp. 35–44, 2002. View at Publisher · View at Google Scholar
  18. A. V. Salnikov, N.-E. Heldin, L. B. Stuhr et al., “Inhibition of carcinoma cell-derived VEGF reduces inflammatory characteristics in xenograft carcinoma,” International Journal of Cancer, vol. 119, no. 12, pp. 2795–2802, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. K. E. De Visser, A. Eichten, and L. M. Coussens, “Paradoxical roles of the immune system during cancer development,” Nature Reviews Cancer, vol. 6, no. 1, pp. 24–37, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. N. Oka, A. Soeda, A. Inagaki et al., “VEGF promotes tumorigenesis and angiogenesis of human glioblastoma stem cells,” Biochemical and Biophysical Research Communications, vol. 360, no. 3, pp. 553–559, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. Y. Takahashi, K. Yamaoka, M. Nishikawa, and Y. Takakura, “Quantitative and temporal analysis of gene silencing in tumor cells induced by small interfering RNA or short hairpin RNA expressed from plasmid vectors,” Journal of Pharmaceutical Sciences, vol. 98, no. 1, pp. 74–80, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. J. P. Ma, Y. Yang, N. Zhang, et al., “Efficient inhibition of lung cancer in murine model by plasmid-encoding VEGF short hairpin RNA in combination with low-dose DDP,” Journal of Experimental & Clinical Cancer Research, vol. 29, article 56, 2010. View at Publisher · View at Google Scholar · View at PubMed
  23. L. G. Presta, H. Chen, S. J. O'Connor et al., “Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders,” Cancer Research, vol. 57, no. 20, pp. 4593–4599, 1997. View at Scopus
  24. N. S. Templeton, D. D. Lasic, P. M. Frederik, H. H. Strey, D. D. Roberts, and G. N. Pavlakis, “Improved DNA: liposome complexes for increased systemic delivery and gene expression,” Nature Biotechnology, vol. 15, no. 7, pp. 647–652, 1997. View at Scopus
  25. J. Tran, J. Rak, C. Sheehan et al., “Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells,” Biochemical and Biophysical Research Communications, vol. 264, no. 3, pp. 781–788, 1999. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus